Adjust Font Size:

Press Releases

Advanced Cell Technology to Present Stem Cell Programs at Rodman & Renshaw’s Annual Healthcare Conference in New York

CEO to Highlight Proprietary Embryonic Stem Cell Technology Platforms and Continued Development of Therapeutic Initiatives

ALAMEDA, Calif.-- (BUSINESS WIRE)"Advanced Cell Technology (ACTC), Inc. (OTCBB:ACTC - News), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, today announced that Chairman and Chief Executive Officer, William M. Caldwell, IV will be a featured presenter at Rodman & Renshaw's 8th Annual Healthcare Conference in New York City on November 6-8.

Mr. Caldwell will review ACTC's proprietary technologies and recent milestones in its mission to drive medically needed stem cell-based therapies to the clinic. He will discuss ACTC's stem cell-related technology platforms, and will spotlight the company's lead programs to develop novel stem cell therapies in the fields of vision, cardiovascular disease and dermal wound repair for scarless healing from burns, surgery and other causes.

ACTC's recent milestones include publication of the company's single cell blastomere technique for generating new embryonic stem cell lines without harming the embryo's potential for life and development. The Company also recently published positive progress in its retinal pigment epithelial (RPE) program, a therapeutic development initiative to develop stem cell-based treatment for certain diseases of the retina.

The Rodman & Renshaw conference will feature presentations from over 300 companies representing the medical device, pharmaceutical and biotechnology industries.

The conference will take place at the Palace Hotel at 455 Madison Ave., in New York, NY. The ACTC presentation is scheduled for 11:40 AM in the Kennedy II room, 4th floor.

A live audio webcast can be accessed on the date of the presentation at "":, and will be archived for 90 days. A downloadable copy of the presentation will also be available on the company's website at "":

For more information about the Rodman & Renshaw conference, visit "":

About Advanced Cell Technology, Inc.

Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

For more information, please visit: "": For investor-specific information and resources, visit "": To read or download Advanced Cell's Investor Fact Sheet, please visit "": To view recent stock quotes and news, visit "":

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.


The Investor Relations Group
Investors: "James Carbonara", 212-825-3210
Media: "Bill Douglass", 212-825-3210
Financial Communications
Trilogy Capital Partners
"Paul Karon", 800-592-6067

Press Contact

Paul Karon

Download PDF


To view PDF Files, you must have Acrobat Reader.

Download Adobe Acrobat